ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Press Release
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Dec 05, 2024 10:22 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (AD).
More info..
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 28, 2024 15:26 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia (early AD).
More info..
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 14:50 JST
The research will be implemented by the Japan Agency forMedical Research and Development (AMED), with NCNP as the lead research institution.
More info..
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 10:51 JST
Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection25 mg" (mecobalamin) has been launched in Japan as a treatment for slowing progression of functionalimpairment in amyotrophic lateral sclerosis.
More info..
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 09:24 JST
Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy.
More info..
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 16:33 JST
Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public understanding of MCI (Mild Cognitive Impairment).
More info..
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 13:31 JST
Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab.
More info..
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 05, 2024 10:35 JST
Eisai Co., Ltd. and Eisai's corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED).
More info..
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Nov 01, 2024 12:56 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
More info..
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 12:56 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually.
More info..
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 31, 2024 10:33 JST
Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held in Madrid, Spain, and virtually.
More info..
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 19:01 JST
Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Abeta)(1) in the brain, a noted cause of Alzheimer's disease(2), in a cohort study conducted in Usuki City, Oita from November 2022.
More info..
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
Oct 17, 2024 14:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-solubleaggregated amyloid-beta (Abeta) monoclonal antibody lecanemab for the treatment of patients with mild cognitive impairment (MCI)due to Alzheimer's disease (AD) and mild AD dementia.
More info..
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging
Oct 16, 2024 18:14 JST
Eisai Co., Ltd. announced today that amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin(R) for Injection 25 mg" (mecobalamin) has received the Good Design Award 2024 (by the Japan Institute of Design Promotion) for its light-proof vial packaging.
More info..
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
Oct 08, 2024 13:00 JST
Eisai Co., Ltd. announced today that it has received approval for "URECE Tablets" (dotinurad) in Thailand as a treatment for gout and hyperuricemia.
More info..
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Oct 02, 2024 10:28 JST
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary recently established in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia).
More info..
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis
Sep 24, 2024 15:06 JST
Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection 25 mg" (mecobalamin) in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis.
More info..
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
Sep 24, 2024 14:01 JST
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements
More info..
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Sep 17, 2024 09:08 JST
These late-breaking data were presented for the first time on September 14 (Central European Summer Time) during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Presentation #LBA3).
More info..
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sep 05, 2024 15:59 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in Barcelona, Spain from September 13 to 17.
More info..
Eisai Announces Status Relating to Acquisition of Own Shares
Sep 02, 2024 14:12 JST
Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act.
More info..
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Aug 22, 2024 18:54 JST
Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.
More info..
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Aug 14, 2024 08:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD).
More info..
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
Aug 06, 2024 12:15 JST
Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.
More info..
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
Jul 31, 2024 12:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually.
More info..
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
Jul 29, 2024 16:59 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD).
More info..
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Jul 25, 2024 09:30 JST
Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society.
More info..
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
Jul 23, 2024 19:23 JST
The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab.
More info..
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
Jul 12, 2024 11:56 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD).
More info..
1
2
3
>>
Last
Latest Release
MHI Group Issues its "SUSTAINABILITY DATABOOK 2024"
Dec 13, 2024 16:31 JST
Notification of Dissolution of Joint Management of LT Metal Co., Ltd. by TANAKA Kikinzoku Kogyo K.K. and LT Corp.
Dec 13, 2024 04:00 JST
MHI's Automated Picking Solution Utilizing Sigma Synx Fully Implemented at Kirin Group's Ebina Logistics Center, the First Such System in Japan
Dec 12, 2024 16:47 JST
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024
Dec 12, 2024 16:27 JST
JCB, AEON Credit Service Indonesia, and Biznet, Indonesia's Leading Internet Provider, Launching AEON Biznet JCB Precious Card, Co-Brand Card
Dec 12, 2024 12:00 JST
JCB to Enable Seamless Transactions on ETA Applications for UK-Bound Travellers
Dec 12, 2024 12:00 JST
Fujitsu develops video analytics AI agent to support safe, secure, and efficient frontline workplaces
Dec 12, 2024 11:06 JST
Fujitsu develops world's first multi-AI agent security technology to protect against vulnerabilities and new threats
Dec 12, 2024 10:28 JST
Intelligent Joy Limited Signs MOU for Strategic Cooperation with First U.S. Capital Group
Dec 11, 2024 19:30 JST
Fujitsu concludes share transfer agreement concerning Fujitsu Communication Services Limited
Dec 11, 2024 16:36 JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 11, 2024 14:45 JST
CELH Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Celsius Holdings, Inc. Investors of Securities Fraud Class Action Lawsuit Deadline
Dec 11, 2024 10:19 JST
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Wolfspeed, Inc.
Dec 11, 2024 10:15 JST
Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program
Dec 11, 2024 10:11 JST
PACS Group, Inc. Investors: January 13, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Dec 11, 2024 10:10 JST
Acadia Healthcare Company, Inc. (ACHC) Investors: December 16, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Dec 11, 2024 10:05 JST
Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform
Dec 10, 2024 19:16 JST
Fujitsu drives business process improvement at Mitsubishi Electric Engineering using SAP Signavio(R)
Dec 10, 2024 11:38 JST
HAIN Premieres December 13, Showcasing the Power of Turkish Cinema
Dec 09, 2024 23:00 JST
Fourteen new trains to drive first rail open access growth
Dec 09, 2024 20:10 JST
More Latest Release >>